Does Aetna cover GLP-1s?
What Aetna (a CVS Health company) says on its own pages (aetna.com), sorted by topic. Your own plan documents decide what you get.
Read Sep 28, 2026. Each line names the plan type it applies to.
Does it cover GLP-1s for weight loss?
- Aetna’s medical Clinical Policy Bulletin 0039 (Weight Reduction Programs and Devices; last review 03/10/2026) says many Aetna benefit plans exclude weight-reduction medications under the pharmacy and/or health benefit.Employer and commercial plans:
Many Aetna benefit plans specifically exclude coverage of weight reduction medications under the pharmacy benefit and/or under the health benefits plan.
aetna.com, Sep 30, 2026 - Aetna’s commercial weight-loss PA policy 6450-C (page dated April 10, 2026) leaves Zepbound vials and Zepbound KwikPens out of its drug table, saying they are covered under the LillyDirect manufacturer program.Employer and commercial plans:
Note: Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths except Zepbound vials and Zepbound Kwikpens, which are covered under the LillyDirect manufacturer program.
aetna.com, Sep 30, 2026 - CVS Health (Aetna’s parent; CVS Caremark is its PBM) said on May 1, 2025 that CVS Caremark would take a formulary action on July 1, 2025 to prefer Wegovy for its members. This is a 2025 statement from the parent company’s investor site, not a 2026 formulary.Employer and commercial plans:
CVS Caremark is partnering with Novo Nordisk to significantly increase access to Wegovy, a GLP-1 drug, for its members at a more affordable price. The Company is taking a formulary action on July 1, 2025 to prefer Wegovy for its members.
investors.cvshealth.com, Sep 30, 2026 - Aetna’s Medicare page (updated July 15, 2026) says Ozempic is not covered by Medicare health plans for GLP-1 weight-loss treatment, and the same is true for Wegovy, Zepbound and Mounjaro.Medicare:
But while the side effects of Ozempic may include weight loss, it isn’t covered by Medicare health plans for GLP-1 weight loss treatment. The same is true for Wegovy, Zepbound and Mounjaro.
aetna.com, Sep 30, 2026
Does it depend on your employer or plan?
- Aetna’s employer GLP-1 page tells plan sponsors they can customize benefits to include or exclude GLP-1 coverage for weight management.Employer and commercial plans:
You can choose to customize your benefits to include or exclude GLP-1 drug coverage for weight management.
aetna.com, Sep 30, 2026 - Aetna’s member pharmacy FAQ says members learn which drugs are covered from their plan documents or member website, and that prior authorization may be required for a drug to be covered for their condition.Employer and commercial plans:
You can learn which drugs are covered under your plan by checking your plan documents. Or log in to your member website. Prior authorization may be required to determine if a drug is covered for your specific condition.
aetna.com, Sep 30, 2026
Prior authorization criteria
- Aetna commercial PA policy 6450-C, the “BMI 35” weight-loss variant (page dated April 10, 2026), requires for adult weight loss a baseline BMI of 35 kg/m2 or more (documentation required; for patients switching from another weight-loss drug, the BMI at the start of any drug therapy counts).Employer and commercial plans:
The patient has a baseline body mass index (BMI) greater than or equal to 35 kg/m2. [NOTE: If the patient is transitioning from another drug therapy for weight loss, please consider their baseline BMI at the start of any drug therapy.] [ACTION REQUIRED: Documentation is required for approval.]
aetna.com, Sep 30, 2026 - Policy 6450-C also requires the patient to have been in a comprehensive weight-management program (behavior change, reduced-calorie diet, more physical activity) with follow-up for at least 6 months before drug therapy.Employer and commercial plans:
The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.
aetna.com, Sep 30, 2026 - For continuation of therapy under 6450-C (criteria listed for Wegovy, tirzepatide and Foundayo requests), the patient must have completed at least 3 months at a stable maintenance dose.Employer and commercial plans:
The patient has completed at least 3 months of therapy with the requested drug at a stable maintenance dose.
aetna.com, Sep 30, 2026 - Continuation under 6450-C (Wegovy, tirzepatide, Foundayo) also requires at least 5% loss of baseline body weight, or maintaining that initial 5% loss.Employer and commercial plans:
The patient has lost at least 5 percent of baseline body weight OR the patient has continued to maintain their initial 5 percent weight loss.
aetna.com, Sep 30, 2026 - In 6450-C’s duration-of-approval section, the Wegovy injection entry for adult weight loss gives 8 months initial approval and 12 months for continuation.Employer and commercial plans:
Reduction in excess body weight, maintenance of weight reduction long term in patients 18 years of age and older: Initial therapy DOA: 8 months; Continuation of therapy DOA: 12 months
aetna.com, Sep 30, 2026 - MASH: 6450-C has MASH (noncirrhotic metabolic dysfunction-associated steatohepatitis) coverage criteria for Wegovy injection only, excluding Wegovy HD 7.2 mg.Employer and commercial plans:
Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (Adult) – Wegovy Injection ONLY (EXCLUDING Wegovy HD 7.2 mg Injection)
aetna.com, Sep 30, 2026 - Aetna’s Medicare page describes Medicare GLP-1 Bridge eligibility (a CMS program): Part D or Medicare Advantage drug coverage plus BMI of 35 or more, or 30 or more with a related health condition.Medicare:
You may qualify if you are enrolled in a standalone Medicare Part D plan or a Medicare Advantage plan with drug coverage and you have a body mass index greater than or equal to 35 or a body mass index greater than or equal to 30 with a related health condition.
aetna.com, Sep 30, 2026 - For the Medicare GLP-1 Bridge, the doctor sends the prior authorization to CMS; Aetna Medicare does not approve Bridge requests.Medicare:
To get approved, your doctor needs to send a request to CMS. This is called prior authorization. It means your doctor must ask for approval before you can get the medication. Aetna Medicare does not approve requests for the Medicare GLP-1 Bridge program.
aetna.com, Sep 30, 2026
Sleep apnea (Zepbound)
- Aetna commercial policy 6450-C covers obstructive sleep apnea only for tirzepatide (Zepbound/Mounjaro).Employer and commercial plans:
Obstructive Sleep Apnea (Adult) – Tirzepatide (Zepbound/Mounjaro) ONLY
aetna.com, Sep 30, 2026 - The 6450-C OSA criteria require an established diagnosis of moderate to severe OSA with an apnea-hypopnea index of at least 15 events per hour on a sleep study.Employer and commercial plans:
The patient has an established diagnosis of moderate to severe OSA with an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device.
aetna.com, Sep 30, 2026 - The 6450-C initial OSA criteria also require a current BMI of 30 kg/m2 or more.Employer and commercial plans:
The patient has a current body mass index (BMI) greater than or equal to 30 kg/m2. [ACTION REQUIRED: Documentation is required for approval.]
aetna.com, Sep 30, 2026 - Aetna’s Medicare page says Medicare Part D may cover GLP-1 medications for conditions such as type 2 diabetes, sleep apnea and MASH.Medicare:
Medications may be covered by Medicare Part D for certain health conditions like Type 2 diabetes, sleep apnea and MASH.
aetna.com, Sep 30, 2026
Heart risk (Wegovy)
- Aetna commercial policy 6450-C has cardiovascular risk-reduction (MACE) criteria for Wegovy only, excluding Wegovy HD 7.2 mg.Employer and commercial plans:
Risk Reduction of Major Adverse Cardiovascular Events (Adult) – Wegovy ONLY (EXCLUDING Wegovy HD 7.2 mg Injection)
aetna.com, Sep 30, 2026 - The 6450-C cardiovascular criteria include a baseline BMI of 27 kg/m2 or more.Employer and commercial plans:
The patient has a baseline body mass index (BMI) greater than or equal to 27 kg/m2. [NOTE: If the patient is transitioning from another drug therapy for weight loss, please consider their baseline BMI at the start of any drug therapy.] [ACTION REQUIRED: Documentation is required for approval.]
aetna.com, Sep 30, 2026 - The 6450-C cardiovascular criteria require that the patient does not have type 2 diabetes; the note says patients with type 2 diabetes may use Ozempic for cardiovascular risk reduction.Employer and commercial plans:
The patient does NOT have type 2 diabetes. [NOTE: Ozempic is indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Patients with type 2 diabetes may be treated for risk reduction of cardiovascular events with Ozempic.]
aetna.com, Sep 30, 2026
Type 2 diabetes
- Aetna commercial PA policy 2439-C (Antidiabetic GLP-1 / GIP-GLP-1 agonists; page dated March 18, 2026) grants type 2 diabetes authorization only when all of its listed criteria are met.Employer and commercial plans:
Authorization may be granted for a diagnosis of type 2 diabetes mellitus when ALL of the following criteria are met:
aetna.com, Sep 30, 2026 - One of the items in policy 2439-C’s type 2 diabetes criteria is inadequate response, intolerance or contraindication to metformin.Employer and commercial plans:
The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to metformin.
aetna.com, Sep 30, 2026 - Aetna’s Medicare page says Part D may cover Ozempic and other GLP-1 drugs for type 2 diabetes, but Medicare generally does not cover them for weight loss.Medicare:
Medicare Part D may cover Ozempic and other GLP-1 drugs when they are prescribed to treat type 2 diabetes. Medicare generally doesn’t cover GLP-1 medications when they are used for weight loss.
aetna.com, Sep 30, 2026
Recent changes
- Aetna’s Medicare page (last updated August 10, 2026) says CMS started the Medicare GLP-1 Bridge program on July 1, 2026.Medicare:
Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) has a new program called the Medicare GLP-1 Bridge program.
aetna.com, Sep 30, 2026 - Under the Bridge, qualifying members pay $50 a month for Foundayo, Wegovy (injection and tablet) or Zepbound (KwikPen only); the program ends December 31, 2027 and is a CMS program, not part of an Aetna Medicare plan.Medicare:
If you qualify, you pay $50 a month for some weight-loss medications, like Foundayo™, Wegovy® (injection and tablet) and Zepbound® (KwikPen® only). The program ends on December 31, 2027. This is a CMS program that’s not part of an Aetna® Medicare plan.
aetna.com, Sep 30, 2026 - CVS Health announced on May 1, 2025 that it would exit the individual exchange business where Aetna independently operates ACA plans for 2026.Individual (ACA) plans:
The Company decided to exit the individual exchange business where Aetna independently operates ACA plans for 2026.
investors.cvshealth.com, Sep 30, 2026
How to check your own plan
- Aetna says members check whether a drug is covered by searching by drug name on their member website.Employer and commercial plans:
To find out if a drug is covered by your plan, use your member website. You can search by drug name to check coverage information.
aetna.com, Sep 30, 2026 - Members can use the “Estimate Medication Cost” box on the member website to see coverage and estimated cost, or call the number on their Aetna member ID card.Employer and commercial plans:
To check the estimated cost of your drug, log in to your member website and fill in the name of your drug into the “Estimate Medication Cost” box. You’ll learn whether your drug is covered and get an estimate of the cost. For more help, call the number on your Aetna member ID card.
aetna.com, Sep 30, 2026
What we could not confirm
- More detail, such as exact BMI cutoffs, is in 6 PDF documents from Aetna, which we have not opened.
- 2 of its pages blocked automated reading.
Next steps
- Prior authorization and appeal letter templates
- Can you use the maker's savings card with your coverage?
- If it is not covered: the lowest verified cash prices
Other insurers: Anthem Blue Cross and Blue Shield, Blue Cross and Blue Shield of Illinois, Blue Shield of California, Cigna, Florida Blue, Highmark, Humana, Independence Blue Cross, Kaiser Permanente, Molina Healthcare, Oscar Health, Premera Blue Cross, UnitedHealthcare, Ambetter, Wellcare, TRICARE, FEP Blue (federal employees), BlueCross BlueShield of South Carolina, CareFirst BlueCross BlueShield